Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma
- Noncontiguous Stage II Small Lymphocytic Lymphoma
- Prolymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia
- Stage I Small Lymphocytic Lymphoma
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage III Small Lymphocytic Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Small Lymphocytic Lymphoma
Interventions
- BIOLOGICAL: MOR00208
- DRUG: lenalidomide
- OTHER: Correlative Studies
Sponsor
Ohio State University Comprehensive Cancer Center
Collaborators